Free NewsletterPro Login

Warning: Undefined variable $stocks in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 448

Warning: foreach() argument must be of type array|object, null given in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 448

Warning: Undefined variable $funds in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 472

Warning: foreach() argument must be of type array|object, null given in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 472
/* the link was here */
×
Free investor livestream — Nov 17

How To Use ChatGPT & Claude To Research Stocks Like A Pro

01
The prompt we use to break down any stock
02
How to fact-check what AI tells you
03
How to compare two stocks in minutes

FDA rejects Summit's lung cancer bid for ivonescimab in EGFR subgroup

Published Nov 15, 2026
Share:
Summary:
  • Summit Therapeutics said the FDA declined to approve ivonescimab for a small subset of advanced non small cell lung cancer.
  • The Complete Response Letter cited no statistically significant overall survival benefit, and slowing disease progression alone was not enough.
  • The decision lands after Summit and partner Akeso said in 2024 that ivonescimab topped Merck's Keytruda in a late stage study in China.

What happened

Summit Therapeutics said the Food and Drug Administration refused to approve its application to use ivonescimab in a niche slice of advanced non small cell lung cancer. The agency sent a Complete Response Letter saying it could not clear the filing as submitted because the drug failed to show a statistically significant improvement in how long patients lived.

The company noted the medicine did hold tumors in check, but regulators said that effect by itself did not justify approval. The decision focused on patients whose cancers are driven by EGFR gene mutations and whose common first line therapy either did not work or stopped working. Summit had sought approval after prior treatment with drugs that target EGFR.

The drug and the data

Ivonescimab was created by Akeso in China, which also sells it there, and Summit is partnering to bring it to the US. The medicine is billed as the most advanced dual action cancer immunotherapy, working both to rally the immune system and to hit a driver of tumor blood vessel growth.

In 2024, Summit and Akeso said the drug beat Merck's Keytruda in a Chinese late stage trial, a splash that helped spark a wave of licensing deals for similar China originated therapies. Since then, ivonescimab has become a bellwether for whether Chinese clinical wins can carry over globally, and Sunday's FDA outcome pushes that proof point further out. Summit pursued this EGFR setting despite prior regulator warnings that its data were not strong enough, and, in an Oct. 27 note, Jefferies called the approval odds "minimal."

New developments in healthcare underscore how staying informed helps investors find opportunities. We're hosting our first ever investor livestream on 11/17 to show you how to use ChatGPT and Claude to invest like a pro, hosted by Briefs Finance CEO Jaspreet Singh. Save your seat.

What the company will do next

Summit said it will keep evaluating the drug in other cancers and is running several additional global Phase 3 studies, including head to head trials against Keytruda. "We are disappointed for patients and their families awaiting additional treatment options in this setting," Chief Executive Officer Bob Duggan said, adding, "Our mission remains to improve outcomes for patients facing significant unmet needs, which is work worth doing."

In September, AstraZeneca Plc said it would put $2 billion into Summit to collaborate on ivonescimab and test it in combinations with AstraZeneca medicines. Should the ongoing trials succeed, Bloomberg Intelligence projects the therapy's total sales could hit $3.8 billion by 2030, and Akeso would collect low double digit royalties from US product sales.

Why investors might care

This setback hits a target population Summit previously pegged at more than 14,000 US patients a year, while Bloomberg Intelligence's Javier Manso Polo now forecasts that potential sales would amount to only $230 million by 2035. The bottom line: the US opportunity now rests on Summit proving ivonescimab's benefit in broader Phase 3 programs, including direct contests with Keytruda.

When industries shift, investors can gain an edge by using smarter research tools. On 11/17, our CEO Jaspreet Singh goes live for our first ever investor livestream on how to use ChatGPT and Claude to invest like a pro. Register to join him.

Disclosure

Recent News

1 2 3 … 129

Get Market Briefs delivered to your inbox every morning for free!

No fluff. No noise. No politics. Just finance news you can read in 5 minutes.

Blogs

November 17, 2026
Is the Stock Market Going to Crash? Why Nvidia and the Fed Have Investors on Edge
  • Tech stocks are selling off because investors don't know who will lead Nvidia, the company that has been funding the AI industry and selling it chips.
  • Inflation has the Federal Reserve planning to raise interest rates, with a hike expected in December, and that puts pressure on homebuyers, private equity and the $40 trillion national debt.
  • Briefs Finance CEO Jaspreet Singh says nobody has a crystal ball, so his rules are to buy when markets are low, hold long term and invest only what you're willing to lose.
Read More
November 16, 2026
The $40 Trillion National Debt: Trump's 4-Part Plan to Make It Feel Smaller
  • The national debt is above $40 trillion, and the Federal Reserve has gone from sending Washington its profits to losing money.
  • President Trump's four-part plan leans on shorter-term debt, stablecoin companies buying Treasuries, a bigger balance sheet and government stakes in private companies.
  • The goal is to outgrow the debt, not pay it off, so Jaspreet Singh points investors to the seven industries where Washington wants growth.
Read More
November 16, 2026
The Fed Is Talking About a Jumbo Interest Rate Hike. It Has No Easy Way Out
  • The Fed makes its next rate decision on December 9 and is now talking about jumbo interest rate hikes of 0.5%, though one in December looks unlikely.
  • Washington will pay a record $1.05 trillion in interest this year on $40 trillion of debt, and that debt resets at higher rates as the Fed hikes.
  • Jaspreet Singh's five moves are to pay down variable-rate debt, earn interest on your savings, know which stocks feel the pressure, look at value and hedge.
Read More
November 16, 2026
Buying on Margin Is at a Record High. Here's the Risk for the Stock Market
  • Margin debt, the money investors borrow to buy stocks, is at a record of around 4.6% of GDP, up from 3.9% in 2021.
  • ETF money has more than tripled in five years to 7% of GDP, while corporate buybacks and 401(k) money sit below their earlier peaks.
  • Margin calls and panic selling can make the next downturn deeper, so Jaspreet Singh keeps buying broad market funds and says most investors should skip margin debt.
Read More
November 16, 2026
Housing Prices Are Falling. Buying a House Still Isn't Cheaper
  • Housing prices have fallen for four straight weeks, but mortgage rates around 7.2% keep the monthly payment about where it was in 2023.
  • Talk of a jumbo Fed rate hike and a plan to sell Fannie Mae and Freddie Mac on the stock market could both push mortgage rates higher.
  • Briefs Finance CEO Jaspreet Singh treats a house as a liability: buy within your budget and let your investments build the wealth.
Read More
November 14, 2026
Nvidia News: Jensen Huang Is Out, and the "Bank" Behind American AI Just Lost Its Founder
  • Jensen Huang is out at Nvidia over affairs with multiple people, and the company he founded has been the bank of American AI, with about $30 billion into OpenAI and $10 billion into Anthropic.
  • A hotter-than-expected inflation report has Fed officials talking about a possible 0.5% hike in December, and gold, silver, and bitcoin fell on the news.
  • President Trump said the US may not need a deal with Iran, keeping oil prices and inflation risk high. Jaspreet Singh breaks down what it all means for AI stocks and your portfolio.
Read More
November 14, 2026
Record Highs, a 57-Year Low in Jobless Claims, and a Stock Market Bubble: Inside the Weirdest Market in History
  • Stocks are booming at the fastest pace in years, jobless claims just hit a 57-year low, and most investors still feel like nobody is hiring.
  • The Fed is protecting the dollar over the economy, oil swings on every Iran headline, and a few AI companies are carrying an S&P 500 where four of five stocks sit in a correction.
  • Jaspreet Singh explains why circular financing between Nvidia, OpenAI, Anthropic, and SpaceX rhymes with 2008's house of cards, and how his three investing pillars handle a stock market bubble.
Read More
November 14, 2026
Is a Recession Coming? The Fed Just Made a U-Turn It Has Only Made Twice in 60 Years
  • The Fed has raised rates, cut them, then raised them again only twice in the last 60 years, and both times the economy fell into a recession and stocks crashed.
  • The same stop-and-go cycle is playing out now, with one big difference: US debt is 125% of GDP today versus about 30% in 1980.
  • In the 1970s gold rose roughly 24x, real estate 157%, stocks lagged, and cash lost half its value. Jaspreet Singh lays out five assets to consider before the next flip.
Read More
November 14, 2026
The 2027 Tax Brackets Are Out: How Some Investors Can Earn $135,300 and Pay $0
  • The IRS 2027 tax plan keeps the same seven rates but widens every bracket and lifts the married-filing-jointly standard deduction to $33,200.
  • The 0% long-term capital gains bracket rises to $102,100, so a household living on $135,300 of investment income could owe $0 in federal income tax.
  • C corporations still pay 21%, small businesses keep the 20% QBI deduction, and the 401(k) limit climbs to $25,500 with an $8,500 catch-up for investors over 50.
Read More
November 14, 2026
Rare Earth Stocks: Why China's January 2027 Ban Could Be the Opportunity of the Decade
  • China plans to block rare earth exports to the US on January 10, 2027, and the US produces effectively zero of the 17 metals that go into phones, cars, dishwashers, and missiles.
  • When China cut off Japan in 2010 and squeezed Germany from 2015, some rare earth prices jumped 18x and 15x, and one rare earth company went bankrupt while another soared.
  • Washington is already putting billions into MP Materials, Vulcan, and a stockpile called Project Vault, and Jaspreet Singh walks through how investors can get exposure to rare earth stocks and ETFs.
Read More
1 2 3 … 33
Share via
Copy link